BioSenic SA
ISIN: BE0974280126 | Ticker: BIOS | LEI: 549300HFIIMTOP1DFR76
Country: Belgium
BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.
Our expertise is focused on bone cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for bone and autoimmune and inflammatory diseases.
BioSenic has a broad and diverse portfolio of solutions in clinical development in a variety of therapeutic areas targeting markets characterized by significant unmet medical needs and limited innovation.
2006
Served areaWorldwide
HeadquartersBâtiment H (bte 24) Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Hainaut – Belgium
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Assets | N/A | 24,835,000.00 | 19,772,000.00 |
| Noncurrent Assets | N/A | 6,019,000.00 | 5,481,000.00 |
| Property Plant And Equipment | N/A | 226,000.00 | 863,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 28,000.00 | 24,000.00 |
| Investments In Associates | N/A | 12,000.00 | 12,000.00 |
| Noncurrent Receivables From Taxes Other Than Income Tax | N/A | 4,456,000.00 | 4,486,000.00 |
| Other Noncurrent Assets | N/A | 1,296,000.00 | 96,000.00 |
| Current Assets | N/A | 18,817,000.00 | 14,291,000.00 |
| Trade And Other Current Receivables | N/A | 3,840,000.00 | 2,581,000.00 |
| Cash and cash equivalents | 8,633,000.00 | 14,648,000.00 | 9,510,000.00 |
| Other Current Assets | N/A | 328,000.00 | 1,000,000.00 |
| Equity And Liabilities | N/A | 24,835,000.00 | 19,772,000.00 |
| Equity | 2,048,000.00 | 3,325,000.00 | -6,765,000.00 |
| Issued Capital | N/A | 8,415,000.00 | 4,924,000.00 |
| Retained Earnings | N/A | -73,080,000.00 | -81,488,000.00 |
| Share Premium | N/A | 67,594,000.00 | 69,499,000.00 |
| Other Reserves | N/A | 396,000.00 | 301,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 3,325,000.00 | -6,765,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 |
| Liabilities | N/A | 21,510,000.00 | 26,537,000.00 |
| Noncurrent Liabilities | N/A | 11,720,000.00 | 19,864,000.00 |
| Other Noncurrent Liabilities | N/A | 0.00 | 112,000.00 |
| Current Liabilities | N/A | 9,790,000.00 | 6,673,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 5,514,000.00 | 4,822,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 0.00 |
| Other Current Liabilities | N/A | 1,199,000.00 | 804,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
|---|---|---|
| Revenue | 1,000,000.00 | 1,000,000.00 |
| Revenue From Interest | 24,000.00 | 25,000.00 |
| Other Income | 2,666,000.00 | 1,745,000.00 |
| Profit Loss From Operating Activities | -15,017,000.00 | -12,026,000.00 |
| Finance Income | 0.00 | 333,000.00 |
| Finance Costs | 747,000.00 | 1,147,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 0.00 | 0.00 |
| Profit Loss Before Tax | -15,754,000.00 | -12,836,000.00 |
| Income Tax Expense Continuing Operations | 78,000.00 | 89,000.00 |
| Profit Loss From Continuing Operations | -15,832,000.00 | -12,925,000.00 |
| Profit Loss From Discontinued Operations | 3,891,000.00 | 0.00 |
| Profit Loss Attributable To Owners Of Parent | -11,940,000.00 | -12,925,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 |
|---|---|---|---|
| Adjustments For Sharebased Payments | N/A | 266,000.00 | -99,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | -88,000.00 | -65,000.00 |
| Cash Flows From Used In Operations | N/A | -18,315,000.00 | -14,565,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 78,000.00 | 89,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -16,082,000.00 | -12,784,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 12,000,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 78,000.00 | 193,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 15,000.00 | 14,000.00 |
| Interest Received Classified As Investing Activities | N/A | 2,000.00 | 3,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 11,908,000.00 | -204,000.00 |
| Payments From Changes In Ownership Interests In Subsidiaries | N/A | 1,956,000.00 | 0.00 |
| Proceeds From Issuing Shares | N/A | 11,783,000.00 | 3,286,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 267,000.00 | 89,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 679,000.00 | 724,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 10,188,000.00 | 7,850,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 6,015,000.00 | -5,138,000.00 |
| Cash and cash equivalents | 8,633,000.00 | 14,648,000.00 | 9,510,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 03.11.22 | Stéphenne Jean | Board | Buy | EUR 9,286.25 |
| 24.10.22 | Pomi Véronique | Board | Buy | EUR 0.00 |
BE0974280126
LEI549300HFIIMTOP1DFR76
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.